Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
In a recent transaction disclosed in an SEC filing, Anthony D’Adamio, Senior Vice President and General Counsel at Bioventus Inc. (NASDAQ:BVS), sold 2,615 shares of the company’s Class A common stock. The shares were sold at a weighted average price of $9.75, generating a total of $25,496. The transaction comes as Bioventus stock has experienced a -9% decline over the past week, though it maintains an impressive 78% gain over the last year. Following this sale, D’Adamio holds 124,449 shares directly. The transaction was conducted on March 17, 2025, as part of a standing 10b5-1 plan to cover taxes upon the vesting of restricted stock units. According to InvestingPro analysis, Bioventus currently appears slightly undervalued, with analyst price targets ranging from $13 to $17, suggesting potential upside. The company maintains a "GOOD" financial health score, with additional insights available in the comprehensive Pro Research Report, part of InvestingPro’s coverage of over 1,400 US stocks.
In other recent news, Bioventus Inc. reported its fourth-quarter 2024 earnings, surpassing revenue expectations with a reported $154 million, a 14% increase year-over-year. This exceeded the forecasted $145.16 million, showcasing the company’s strong performance in its Surgical Solutions and Pain Treatments segments. Bioventus also announced a full-year adjusted EBITDA of $109 million, reflecting a 23% rise compared to the previous year. The company improved its financial health by paying down nearly $50 million in debt. Looking forward, Bioventus projects 2025 net sales between $560 million and $570 million, indicating 6-8% organic growth. The company aims for an adjusted EBITDA of $112-$116 million, with expectations for the lowest revenue and EBITDA in Q1 and the highest in Q4. Analysts from Craig Hallum and JPMorgan noted Bioventus’s strong market position, with particular emphasis on its growth potential in the Pain Treatments segment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.